Molecure S.A.

WSE:MOC Rapport sur les actions

Capitalisation boursière : zł173.4m

Molecure Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Marcin Szumowski

Directeur général

zł473.2k

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur généralno data
Propriété du PDG0.7%
Durée moyenne d'occupation des postes de direction3.8yrs
Durée moyenne du mandat des membres du conseil d'administration2.8yrs

Mises à jour récentes de la gestion

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04
OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24
Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02
Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

PDG

Marcin Szumowski

no data

Titularisation

zł473,205

Compensation

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Marcin Szumowski
Co-Founderno datazł473.21k0.70%
PLN 1.2m
Slawomir Broniarek
CFO & Member of the Management Boardno datazł421.09k0.20%
PLN 355.4k
Zbigniew Zaslona
Chief Scientific Officer & Member of Management Board2.8yrszł473.21k0.11%
PLN 194.6k
Agnieszka Rajczuk-Szczepanska
Member of Management Board & HR Director4.8yrszł348.41k0.034%
PLN 59.7k
Adam Golebiowski
Co-Founder & VP of Research Chemistry12.8yrszł500.00k3.01%
PLN 5.2m
Jacek Olczak
Co-Founder & Head of Medicinal Chemistryno datapas de donnéespas de données
Piotr Iwanowski
Chief Medical Officer & Member of Management Boardless than a yearpas de donnéespas de données
Magdalena Tyszkiewicz
Head of CMC4.8yrspas de donnéespas de données
Marta Borkowska
Director of the Management Board Office2.8yrspas de donnéespas de données

3.8yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de MOC est considérée comme expérimentée (ancienneté moyenne 3.8 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Luke O'Neill
Member of Scientific Advisory Boardno datapas de donnéespas de données
Bart Lambrecht
Member of Scientific Advisory Boardno datapas de donnéespas de données
Tomasz Piec
Vice Chairman of the Supervisory Board4.8yrszł133.62kpas de données
Douglas Hay
Member of Scientific Advisory Boardno datapas de donnéespas de données
Paul Van Der Horst
Independent Chairman of the Supervisory Board2.8yrszł132.99k0.059%
PLN 103.0k
Nancy Van Osselaer
Independent Member of the Supervisory Board2.8yrszł124.22kpas de données
Agnieszka Motyl
Member of the Supervisory Board1.3yrszł44.45kpas de données
Pawel Trawkowski
Independent Member of the Supervisory Board2.4yrszł124.22kpas de données

2.8yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Le conseil d'administration de la MOC n'est pas considéré comme expérimenté ( 2.8 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.